Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Voice features and deep learning models for identifying acute decompensated heart failure.

Digital health·2026
Same author

Prognostic significance of high Lipoprotein(a) levels in patients with coronary artery spasm.

Heart and vessels·2026
Same author

Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort.

Frontiers in cardiovascular medicine·2026
Same author

Comprehensive Assessment of Kounis Syndrome Secondary to Carboplatin Chemotherapy: A Case Report.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi·2026
Same author

Effectiveness and Safety of Biodegradable Polymer-Coated Everolimus-Eluting Stent in Multivessel Coronary Artery Disease in Routine Clinical Practice: A Korean Multicenter, Prospective, and Observational Study.

Journal of Korean medical science·2026
Same author

LOw-Dose RAbeprazole Therapy for Reducing Gastrointestinal Events in Patients with High Bleeding Risk (LORA-HBR): A Prospective, Multicenter, Interventional Study.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins do not decrease small, dense low-density lipoprotein.

Cheol Ung Choi1, Hong Seog Seo, Eun Mi Lee

  • 1Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Republic of Korea.

Texas Heart Institute Journal
|September 17, 2010
PubMed
Summary

Statin therapy increases the proportion of small, dense low-density lipoprotein (LDL) particles, despite lowering overall LDL cholesterol. This finding may offer new insights into atherosclerosis progression.

Keywords:
Antilipemic agents/therapeutic usearteriosclerosis/bloodbiological markers/bloodcholesterol, LDL/analysis/blood/classification/drug effectscoronary artery disease/prevention & control/therapyhyperlipidemias/prevention & controllipidslipoproteins, LDL/blood/chemistryparticle size

Related Experiment Videos

Last Updated: Jun 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Pharmacology

Background:

  • Low-density lipoprotein (LDL) subfractions are increasingly recognized as important in cardiovascular risk assessment.
  • Statins are primary lipid-lowering drugs, but their precise effects on LDL subfractions require further elucidation.
  • Small, dense LDL particles are considered more atherogenic than large, buoyant LDL particles.

Purpose of the Study:

  • To investigate the impact of statin therapy on the proportion of small, dense LDL particles in patients with and without coronary artery disease.
  • To compare LDL subfraction profiles between statin-treated patients and a control group.

Main Methods:

  • Observational study involving 612 patients, stratified into statin-treated (n=172) and control (n=440) groups.
  • Density-gradient ultracentrifugation was used to measure LDL subfractions.
  • Patients were further subdivided based on the presence or absence of coronary artery disease.

Main Results:

  • Statin treatment significantly lowered total cholesterol, LDL cholesterol, apolipoprotein B, and the LDL cholesterol/apolipoprotein B ratio.
  • The proportion of small, dense LDL was significantly higher in the statin group (42.9% ± 9.5%) compared to the control group (41.3% ± 8.5%; P=0.046).
  • The proportion of large, buoyant LDL was lower in the statin group (23.6% ± 7.5%) compared to the control group (25.4% ± 7.9%; P=0.011).

Conclusions:

  • Statin therapy increases the proportion of small, dense LDL particles, irrespective of coronary artery disease status.
  • While statins reduce overall LDL cholesterol and absolute amounts of LDL subfractions, they appear to shift the LDL profile towards smaller, denser particles.
  • Further research is warranted to confirm these findings and explore the implications for atherogenesis and atherosclerosis progression.